Beckman Coulter Life Sciences Names Joe Fox President

With the an­tic­i­pa­tion that more gene ther­a­pies will en­ter the mar­ket, man­u­fac­tur­ers could strug­gle to meet de­mand if lentivi­ral vec­tor short­age risk is not tack­led,

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Pancreatic Cancer.

Overconsumption of beverages with added sugar or artificial sweetener, already associated with several cardiometabolic diseases, showed new links to atrial fibrillation (Afib or AF) in